vs
Side-by-side financial comparison of Hippo Holdings Inc. (HIPO) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $120.4M, roughly 1.5× Hippo Holdings Inc.). Hippo Holdings Inc. runs the higher net margin — 5.0% vs 1.6%, a 3.3% gap on every dollar of revenue. On growth, Hippo Holdings Inc. posted the faster year-over-year revenue change (18.2% vs 5.0%). Over the past eight quarters, Hippo Holdings Inc.'s revenue compounded faster (18.9% CAGR vs -0.2%).
Hippo Valley Estate is a sugar estate found near the town of Chiredzi in Chiredzi District of southeastern Zimbabwe, on the Runde River near the border with Mozambique.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
HIPO vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $120.4M | $177.4M |
| Net Profit | $6.0M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 5.6% | 3.9% |
| Net Margin | 5.0% | 1.6% |
| Revenue YoY | 18.2% | 5.0% |
| Net Profit YoY | -86.4% | — |
| EPS (diluted) | $0.31 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $120.4M | $196.9M | ||
| Q3 25 | $120.6M | $179.5M | ||
| Q2 25 | $117.3M | $181.1M | ||
| Q1 25 | $110.3M | $168.9M | ||
| Q4 24 | $101.9M | $187.3M | ||
| Q3 24 | $95.5M | $168.6M | ||
| Q2 24 | $89.6M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $6.0M | — | ||
| Q3 25 | $98.1M | $5.4M | ||
| Q2 25 | $1.3M | $-4.8M | ||
| Q1 25 | $-47.7M | $4.8M | ||
| Q4 24 | $44.2M | — | ||
| Q3 24 | $-8.5M | $-143.5M | ||
| Q2 24 | $-40.5M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 5.6% | 1.2% | ||
| Q3 25 | 81.3% | 3.5% | ||
| Q2 25 | 3.4% | 4.7% | ||
| Q1 25 | -41.3% | 1.2% | ||
| Q4 24 | 46.3% | 13.2% | ||
| Q3 24 | -5.4% | -82.8% | ||
| Q2 24 | -40.7% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 5.0% | — | ||
| Q3 25 | 81.3% | 3.0% | ||
| Q2 25 | 1.1% | -2.7% | ||
| Q1 25 | -43.2% | 2.8% | ||
| Q4 24 | 43.4% | — | ||
| Q3 24 | -8.9% | -85.1% | ||
| Q2 24 | -45.2% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.31 | $0.05 | ||
| Q3 25 | $3.77 | $0.12 | ||
| Q2 25 | $0.05 | $-0.11 | ||
| Q1 25 | $-1.91 | $0.10 | ||
| Q4 24 | $1.81 | $0.38 | ||
| Q3 24 | $-0.34 | $-3.11 | ||
| Q2 24 | $-1.64 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $218.3M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $436.1M | $653.9M |
| Total Assets | $1.9B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $218.3M | $238.4M | ||
| Q3 25 | $247.7M | $246.3M | ||
| Q2 25 | $198.9M | $445.9M | ||
| Q1 25 | $140.9M | $493.6M | ||
| Q4 24 | $197.6M | $484.6M | ||
| Q3 24 | $191.2M | $453.8M | ||
| Q2 24 | $175.9M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $436.1M | $693.1M | ||
| Q3 25 | $421.5M | $727.2M | ||
| Q2 25 | $332.5M | $757.8M | ||
| Q1 25 | $322.8M | $798.5M | ||
| Q4 24 | $362.1M | $778.3M | ||
| Q3 24 | $326.4M | $749.6M | ||
| Q2 24 | $322.6M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.9B | $1.3B | ||
| Q3 25 | $1.9B | $1.3B | ||
| Q2 25 | $1.7B | $1.5B | ||
| Q1 25 | $1.5B | $1.6B | ||
| Q4 24 | $1.5B | $1.6B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.5B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.2M | — |
| Free Cash FlowOCF − Capex | $9.1M | — |
| FCF MarginFCF / Revenue | 7.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | 1.53× | — |
| TTM Free Cash FlowTrailing 4 quarters | $14.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $9.2M | $43.7M | ||
| Q3 25 | $16.9M | $60.8M | ||
| Q2 25 | $24.7M | $12.0M | ||
| Q1 25 | $-35.6M | $35.5M | ||
| Q4 24 | $47.5M | $33.1M | ||
| Q3 24 | $46.8M | $53.9M | ||
| Q2 24 | $-10.6M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $9.1M | $43.5M | ||
| Q3 25 | $16.8M | $57.0M | ||
| Q2 25 | $24.6M | $9.3M | ||
| Q1 25 | $-35.7M | $26.9M | ||
| Q4 24 | $47.2M | $31.0M | ||
| Q3 24 | — | $49.8M | ||
| Q2 24 | $-10.7M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 7.6% | 22.1% | ||
| Q3 25 | 13.9% | 31.7% | ||
| Q2 25 | 21.0% | 5.1% | ||
| Q1 25 | -32.4% | 15.9% | ||
| Q4 24 | 46.3% | 16.6% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | -11.9% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 0.1% | ||
| Q3 25 | 0.1% | 2.2% | ||
| Q2 25 | 0.1% | 1.5% | ||
| Q1 25 | 0.1% | 5.1% | ||
| Q4 24 | 0.3% | 1.1% | ||
| Q3 24 | 0.0% | 2.4% | ||
| Q2 24 | 0.1% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.53× | — | ||
| Q3 25 | 0.17× | 11.20× | ||
| Q2 25 | 19.00× | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HIPO
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
